The ruling shows Novo Nordisk’s confidence that the supply of semaglutide will be stable for now.
Key Takeaways Hims & Hers Health shares swooned after the Food & Drug Administration said the active ingredient in Ozempic ...
Shares of Hims & Hers Health (NYSE: HIMS) are falling on Friday. The company's stock lost 23.2% as of 1 p.m. ET and lost as ...
28mon MSN
Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug ...
Poor earnings results and a slump in the major gauges leave the weekend uncertain as futures hug the flatline.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results